UT Austin-founded Kyn Therapeutics has been backed by Celgene in a strategic pact that also includes a $80m non-equity payment, giving Celgene the right to license two programs.
Kyn Therapeutics, a US-based developer of immunometabolic cancer drugs spun out from University of Texas (UT) at Austin, today secured funding from pharmaceutical company Celgene as part of a strategic partnership. Founded in 2016, Kyn Therapeutics is working on cancer drugs that will target interactions between organism-sustaining metabolic processes and the immune system, a group…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
